

---

# Contents

<b>Imatinib Mesylate</b> . . . . .	1
Cornelius F. Waller	
1 Introduction. . . . .	2
2 Structure and Mechanisms of Action . . . . .	4
3 Preclinical Data . . . . .	5
4 Clinical Data in CML. . . . .	7
4.1 Phase I Trials. . . . .	7
4.2 Phase II Studies . . . . .	8
4.3 Phase III Study (IRIS Trial). . . . .	9
5 Treatment Recommendations for the Use of Imatinib in Chronic Phase CML. . . . .	10
6 Imatinib in Combination with Other Drugs . . . . .	12
7 Imatinib: Other Targets . . . . .	13
8 Side Effects/Toxicity . . . . .	14
9 Clinical Pharmacology and Drug Interactions . . . . .	17
10 Biomarkers . . . . .	18
10.1 CML. . . . .	18
10.2 GIST. . . . .	18
11 Summary and Perspectives . . . . .	19
References . . . . .	20
<b>Dasatinib</b> . . . . .	27
Markus Lindauer and Andreas Hochhaus	
1 Introduction. . . . .	28
2 Structure and Mechanism of Action . . . . .	29
3 Preclinical Data . . . . .	31
3.1 Inhibition of ABL. . . . .	31
3.2 Inhibition of SRC. . . . .	32
3.3 Inhibition of KIT . . . . .	33
3.4 Inhibition of Platelet-Derived Growth Factor Receptor (PDGFR) $\alpha$ and $\beta$ Tyrosine Kinases . . . . .	33
3.5 Inhibition of Ephrin Receptor Tyrosine Kinases. . . . .	34
3.6 Inhibition of TEC Family Kinases and BTK . . . . .	34

4	Clinical Data . . . . .	35
4.1	Pharmacokinetic Profile . . . . .	35
4.2	Clinical Trials with Dasatinib . . . . .	35
4.3	Clinical Trials with Dasatinib in CML Patients: Overview . . .	35
4.4	Dasatinib in Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) . . . . .	42
4.5	Dasatinib in Philadelphia-Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis . . . . .	43
4.6	Dasatinib in the Treatment of Solid Tumors . . . . .	45
5	Toxicity . . . . .	48
6	Drug Interactions . . . . .	53
7	Biomarkers . . . . .	54
8	Summary and Perspectives . . . . .	55
	References . . . . .	56
	<b>Nilotinib</b> . . . . .	67
	Benjamin N. Ostendorf, Philipp le Coutre, Theo D. Kim and Alfonso Quintás-Cardama	
1	Introduction . . . . .	68
2	Structure and Mechanism of Action . . . . .	69
3	Preclinical Data . . . . .	69
4	Clinical Data . . . . .	70
4.1	Nilotinib Phase I Trial . . . . .	70
4.2	Nilotinib Second- and Third-Line Therapy . . . . .	71
4.3	Nilotinib First-Line Therapy . . . . .	72
4.4	Resistance to Nilotinib . . . . .	73
5	Toxicity . . . . .	74
6	Drug Interactions . . . . .	76
7	Biomarkers . . . . .	77
8	Summary and Perspectives . . . . .	77
	References . . . . .	78
	<b>Bosutinib: A Novel Second-Generation Tyrosine Kinase Inhibitor</b> . . . . .	81
	Susanne Isfort, Gunhild Keller-v. Amsberg, Philippe Schafhausen, Steffen Koschmieder and Tim H. Brümmendorf	
1	Structure and Mechanism of Action . . . . .	82
1.1	Chemical Structure . . . . .	82
1.2	Mechanism of Action (Target Profile). . . . .	82
1.3	SRC Kinase Inhibition . . . . .	83
1.4	ABL and BCR-ABL Inhibition . . . . .	83

2	Preclinical Data . . . . .	84
2.1	BCR-ABL-Dependent Diseases . . . . .	84
2.2	Potential New Hematologic Diseases/Targets . . . . .	86
2.3	Breast Cancer . . . . .	86
2.4	Colorectal Cancer . . . . .	87
2.5	Non-small Cell Lung Cell Cancer . . . . .	87
2.6	Polycystic Kidney Disease . . . . .	87
3	Clinical Data . . . . .	88
3.1	Bosutinib in Treatment-Resistant-/Intolerant CML . . . . .	88
3.2	Bosutinib in CML First-Line Treatment . . . . .	91
3.3	Bosutinib in Solid Tumors . . . . .	92
4	Toxicity . . . . .	92
5	Drug Interactions . . . . .	93
6	Biomarkers . . . . .	93
7	Summary and Perspectives . . . . .	94
	References . . . . .	95

### **Ponatinib: A Third-Generation Inhibitor**

	<b>for the Treatment of CML . . . . .</b>	<b>99</b>
	Julius Wehrle, Heike L. Pahl and Nikolas von Bubnoff	
1	Resistance to Treatment in CML . . . . .	100
2	Second-Generation Inhibitors . . . . .	101
3	Ponatinib: A New Third-Generation Inhibitor . . . . .	101
	References . . . . .	105

### **Erlotinib . . . . . 109**

	M. Steins, M. Thomas and M. Geißler	
1	Introduction . . . . .	110
2	Mechanism of Action . . . . .	110
3	Non-Small Cell Lung Cancer . . . . .	112
4	Pancreatic Adenocarcinoma . . . . .	115
5	Hepatocellular Carcinoma . . . . .	118
6	Other Tumour Entities . . . . .	120
	References . . . . .	120

### **Lapatinib . . . . . 125**

	Minna Nolting, Tanja Schneider-Merck and Martin Trepel	
1	Introduction . . . . .	126
1.1	The Epidermal Growth Factor Receptor Family of Tyrosine Kinases . . . . .	126
1.2	Human Epidermal Growth Factor Receptors and Their Inhibition in Cancer . . . . .	127
2	Structure and Mechanism of Action . . . . .	128
3	Pharmacology . . . . .	130

4	Results from Clinical Trials . . . . .	130
4.1	Efficacy in Breast Cancer . . . . .	130
4.2	Efficacy in Gastroesophageal Cancer . . . . .	137
4.3	Tolerability . . . . .	138
5	Conclusion and Future Perspectives . . . . .	139
	References . . . . .	140
	<b>Sorafenib: Targeting Multiple Tyrosine Kinases in Cancer . . . . .</b>	<b>145</b>
	Jens Hasskarl	
1	Introduction. . . . .	146
2	Structure and Mechanism of Action . . . . .	147
3	Clinical Data . . . . .	149
3.1	Phase I . . . . .	149
3.2	Experience in Special Patient Populations . . . . .	149
3.3	Experience in Pediatric Patients . . . . .	150
3.4	Active Clinical Trials . . . . .	151
3.5	Sorafenib in the Treatment of Renal Cell Cancer . . . . .	151
3.6	Sorafenib in the Treatment of Hepatocellular Cancer . . . . .	153
3.7	Sorafenib in the Treatment of Lung Cancer . . . . .	153
3.8	Sorafenib in the Treatment of Breast Cancer . . . . .	154
3.9	Sorafenib in the Treatment of Malignant Melanoma . . . . .	154
3.10	Sorafenib in the Treatment of Prostate Cancer . . . . .	154
3.11	Sorafenib in the Treatment of Head and Neck Cancer . . . . .	155
3.12	Sorafenib in the Treatment of Ovarian Cancer . . . . .	155
3.13	Sorafenib in the Treatment of Brain Tumors . . . . .	155
3.14	Sorafenib in the Treatment of Thyroid Cancer . . . . .	155
3.15	Sorafenib in the Treatment of Hematologic Diseases . . . . .	156
4	Clinical Safety Profile of Sorafenib . . . . .	157
5	Conclusion and Future Perspectives . . . . .	157
	References . . . . .	157
	<b>Sunitinib in the Treatment of Advanced Solid Tumors . . . . .</b>	<b>165</b>
	Amal Imbulgoda, Daniel Y. C. Heng and Christian Kollmannsberger	
1	Structure and Mechanism of Action . . . . .	166
2	Preclinical Data . . . . .	166
3	Clinical Data . . . . .	167
3.1	Renal Cell Carcinoma . . . . .	167
3.2	Gastrointestinal Stromal Tumors . . . . .	170
3.3	Pancreatic Neuroendocrine Tumors . . . . .	172
3.4	Other Solid Tumors . . . . .	174
4	Toxicity . . . . .	175
5	Drug Interactions . . . . .	178
6	Biomarkers . . . . .	178

7	Summary and Perspectives . . . . .	179
	References . . . . .	179
	<b>Regorafenib</b> . . . . .	185
	Thomas J. Ettrich and Thomas Seufferlein	
1	Structure, Mechanism of Action, and Pharmacokinetics . . . . .	186
1.1	Mechanism of Action . . . . .	186
1.2	Pharmacokinetics and Elimination . . . . .	186
1.3	Regorafenib in Renal or Hepatic Impairment . . . . .	187
2	Preclinical Data . . . . .	187
3	Clinical Data . . . . .	188
3.1	Regorafenib in Metastatic Colorectal Cancer . . . . .	188
3.2	Regorafenib in Metastatic Gastrointestinal Stromal Tumors . . . . .	189
3.3	Regorafenib in Hepatocellular Carcinoma . . . . .	191
3.4	Regorafenib in Metastatic Renal Cell Carcinoma . . . . .	191
3.5	Regorafenib in Soft Tissue Sarcoma . . . . .	192
4	Detailed Analysis of Toxicity . . . . .	192
4.1	Dermatological Toxicity . . . . .	192
4.2	Hypertension, Cardiac Ischemia, and Infarction . . . . .	193
4.3	Hepatotoxicity . . . . .	193
4.4	Gastrointestinal Perforation or Fistula . . . . .	193
4.5	Hemorrhage . . . . .	193
4.6	Embryo–Fetal Toxicity . . . . .	194
5	Drug Interactions . . . . .	194
5.1	Effect of Strong CYP3A4 Inducers . . . . .	194
5.2	Effect of Strong CYP3A4 Inhibitors . . . . .	194
5.3	Effect of Regorafenib on UGT1A1 Substrates . . . . .	194
6	Biomarkers . . . . .	194
7	Summary and Perspectives . . . . .	195
	References . . . . .	195
	<b>Crizotinib</b> . . . . .	197
	David F. Heigener and Martin Reck	
1	Structure and Mechanism of Action . . . . .	198
2	Preclinical Data . . . . .	198
3	Clinical Data . . . . .	199
3.1	NSCLC . . . . .	199
3.2	Other Entities . . . . .	202
4	Toxicity . . . . .	202
5	Drug Interactions . . . . .	202
6	Biomarkers . . . . .	203
7	Summary and Perspectives . . . . .	203
	References . . . . .	204

**Cabozantinib: A MET, RET, and VEGFR2 Tyrosine****Kinase Inhibitor . . . . . 207**

Carsten Gröllich

1	Introduction. . . . .	208
2	Preclinical Properties and Pharmacokinetics . . . . .	209
3	Clinical Trials . . . . .	210
3.1	Phase I . . . . .	210
3.2	Phase III EXAM Trial. . . . .	210
3.3	Phase II Trial in Prostate Cancer . . . . .	211
4	Discussion. . . . .	212
	References . . . . .	214

**Vemurafenib . . . . . 215**

Claus Garbe, Sail Abusaif and Thomas K. Eigentler

1	Introduction. . . . .	216
2	Structure and Mechanism of Action . . . . .	217
3	Preclinical Data . . . . .	218
4	Pharmacokinetics and Drug Interactions . . . . .	218
5	Vemurafenib in Melanoma . . . . .	219
6	Toxicity . . . . .	220
7	Vemurafenib in Colorectal Cancer . . . . .	221
8	Vemurafenib in Papillary Thyroid Cancer. . . . .	221
9	Vemurafenib in Non-Small-Cell Lung Cancer . . . . .	222
10	Vemurafenib in Hairy Cell Leukaemia . . . . .	222
11	Biomarkers and Monitoring of Vemurafenib Treatment . . . . .	222
12	Summary and Perspectives . . . . .	223
	References . . . . .	223

**Dabrafenib . . . . . 227**

Radhika Kainthla, Kevin B. Kim and Gerald S. Falchook

1	Introduction. . . . .	228
2	Mechanism of Action. . . . .	228
3	Preclinical Data . . . . .	229
3.1	Dabrafenib Activity in V600 BRAF-Mutant Cell Lines. . . . .	229
3.2	Dabrafenib and Immune Modulation. . . . .	230
3.3	Mechanisms of Dabrafenib Resistance . . . . .	230
4	Metastatic Melanoma . . . . .	232
4.1	Monotherapy . . . . .	232
4.2	Monotherapy in Brain Metastasis . . . . .	233
4.3	Combination Therapy with Trametinib . . . . .	234

5	Other Cancers With V600E BRAF Mutations . . . . .	235
5.1	Dabrafenib Monotherapy . . . . .	235
5.2	Combination Therapy with Trametinib in Colorectal Cancer (CRC). . . . .	235
6	Toxicity . . . . .	236
7	Drug Interactions . . . . .	236
8	Biomarkers . . . . .	237
8.1	Predictors of Response . . . . .	237
8.2	Pharmacodynamic Markers . . . . .	237
9	Summary and Perspectives . . . . .	237
	References . . . . .	238
	<b>Trametinib</b> . . . . .	241
	Robert Zeiser	
1	Structure and Mechanism of Action . . . . .	242
2	Preclinical Data . . . . .	242
3	Clinical Data . . . . .	244
4	Toxicity . . . . .	245
5	Drug Interactions . . . . .	246
6	Biomarkers . . . . .	246
7	Summary and Perspectives . . . . .	247
	References . . . . .	247
	<b>Ruxolitinib</b> . . . . .	249
	Heiko Becker, Monika Engelhardt, Nikolas von Bubnoff and Ralph Wäsch	
1	Structure and Mechanism of Action . . . . .	250
2	Preclinical Data . . . . .	250
3	Clinical Data . . . . .	251
4	Toxicity . . . . .	254
5	Drug Interactions . . . . .	255
6	Biomarkers . . . . .	256
7	Summary and Perspectives . . . . .	256
	References . . . . .	256
	<b>Ibrutinib</b> . . . . .	259
	Mark-Alexander Schwarzbich and Matthias Witzens-Harig	
1	Structure and Mechanism of Action . . . . .	260
2	Preclinical Data . . . . .	262
3	Clinical Data . . . . .	263
4	Toxicity . . . . .	264
5	Drug Interactions . . . . .	265
6	Summary and Perspectives . . . . .	265
	References . . . . .	265

<b>Decitabine</b> . . . . .	269
Björn Hackanson and Michael Daskalakis	
1 Introduction . . . . .	270
2 Structure and Mechanism of Action . . . . .	271
2.1 Single-Agent Decitabine in MDS and AML . . . . .	271
2.2 Combination Treatment with Decitabine in MDS and AML . . . . .	275
2.3 Decitabine as a Preparative Agent for Allogeneic Stem Cell Transplantation . . . . .	278
2.4 Immunomodulation with Decitabine . . . . .	279
2.5 Decitabine Treatment in Other Diseases . . . . .	281
3 Toxicity . . . . .	286
4 Drug Interactions . . . . .	287
5 Biomarkers . . . . .	287
6 Summary and Perspectives . . . . .	287
References . . . . .	288
<b>5-Azacytidine/5-Azacitidine</b> . . . . .	299
Antonia M. S. Müller and Mareike Florek	
1 Introduction . . . . .	300
2 Structure and Mechanism of Action . . . . .	301
2.1 Structure . . . . .	301
2.2 Mechanism of Action . . . . .	301
2.3 Pharmacology, Bioavailability, Half-Life, Elimination, Drug–Drug Interactions . . . . .	302
3 Toxicity . . . . .	303
3.1 Safety, Side Effects, and Contraindications . . . . .	303
4 Preclinical Data . . . . .	305
5 Clinical Use of 5-Azacytidine . . . . .	306
5.1 Early Studies . . . . .	306
5.2 Randomized Phase III Studies of 5-Azacytidine . . . . .	307
5.3 Current Questions and Preliminary Results . . . . .	310
6 Conclusion and Perspective . . . . .	317
References . . . . .	318
<b>Bortezomib</b> . . . . .	325
Hermann Einsele	
1 Mode of Action . . . . .	326
2 Antitumor Effects . . . . .	327
3 Clinical Application of Proteasome Inhibitors . . . . .	329
4 Bortezomib . . . . .	330
5 Bortezomib-Based Combination Therapy for Multiple Myeloma . . . . .	332
6 Treatment Options for Patients Eligible for Transplant . . . . .	333
7 Next-Generation Proteasome Inhibitors . . . . .	335
References . . . . .	337



<b>Lenalidomide</b> . . . . .	347
Katja Weisel and Lothar Kanz	
1 Introduction. . . . .	348
2 Structure and Mechanism of Action . . . . .	348
3 Clinical Data . . . . .	349
4 Lenalidomide in Multiple Myeloma . . . . .	349
5 Lenalidomide in Relapsed Multiple Myeloma . . . . .	350
6 Lenalidomide in Newly Diagnosed Multiple Myeloma . . . . .	350
7 Maintenance Treatment with Lenalidomide in Multiple Myeloma After ASCT . . . . .	351
8 Lenalidomide in MDS . . . . .	352
9 Lenalidomide in Other Hematological Malignancies . . . . .	353
10 Lenalidomide in Solid Tumors . . . . .	354
11 Conclusions and Future Perspectives . . . . .	355
References . . . . .	355
<b>Pomalidomide</b> . . . . .	359
Monika Engelhardt, Ralph Wäsch, Heike Reinhardt and Martina Kleber	
1 Structure and Mechanism of Action . . . . .	360
2 Preclinical Data . . . . .	361
3 Clinical Data . . . . .	364
4 MM . . . . .	364
5 AL Amyloidosis . . . . .	367
6 Myelofibrosis . . . . .	367
7 Toxicity . . . . .	368
8 Drug Interactions . . . . .	369
9 Biomarkers . . . . .	369
10 Summary and Perspectives . . . . .	370
References . . . . .	370
<b>Everolimus</b> . . . . .	373
Jens Hasskarl	
1 Introduction. . . . .	374
2 Structure and Mechanism of Action . . . . .	376
3 Preclinical Data . . . . .	376
4 Clinical Data . . . . .	377
4.1 Pharmacokinetics and Pharmacodynamics . . . . .	377
4.2 Clinical Development of Everolimus. . . . .	378
5 Toxicity . . . . .	387
6 Drug Interactions . . . . .	387
7 Biomarkers . . . . .	387
8 Summary and Perspectives . . . . .	388
References . . . . .	388

<b>Temsirolimus</b> . . . . .	393
Michael Schulze, Christian Stock, Massimo Zaccagnini, Dogu Teber and Jens J. Rassweiler	
1 Introduction. . . . .	394
2 Development . . . . .	395
3 Structure and Mechanism of Action . . . . .	395
4 Clinical Data . . . . .	397
5 Safety and Efficacy . . . . .	397
6 Side Effects. . . . .	399
7 Conclusion and Future Perspectives . . . . .	400
References . . . . .	401
<b>Vismodegib</b> . . . . .	405
F. Meiss and R. Zeiser	
1 Introduction. . . . .	406
2 Structure and Mechanism of Action . . . . .	407
2.1 Structure . . . . .	407
2.2 Mechanism of Action . . . . .	407
3 Preclinical Data . . . . .	408
4 Clinical Data . . . . .	408
4.1 Vismodegib in Basal Cell Carcinoma (BCC) . . . . .	408
4.2 Vismodegib in Colorectal Cancer . . . . .	410
4.3 Vismodegib in Ovarian Cancer . . . . .	410
4.4 Vismodegib in Small Lung Cell Cancer . . . . .	411
4.5 Vismodegib in Hematologic Diseases . . . . .	411
4.6 Vismodegib in Medulloblastoma . . . . .	412
5 Toxicity . . . . .	412
6 Drug Interactions . . . . .	414
7 Summary and Perspectives . . . . .	414
References . . . . .	415

Small Molecules in Oncology

Martens, U.M. (Ed.)

2014, XVI, 417 p. 46 illus., 26 illus. in color., Hardcover

ISBN: 978-3-642-54489-7